Metabolomic Description of Ivacaftor Elevating Polymyxin B Mediated Antibacterial Activity in Cystic Fibrosis

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

1. In Vitro Restoration of Colistin Susceptibility by Ivacaftor Synergy with Limited Reproducibility in a Murine Pneumonia Model.Antibiotics (Basel, Switzerland) · 2026
   Article
2. Novel therapeutic approach for the treatment of cystic fibrosis based on freeze-dried tridrug microparticles to treat cystic fibrosis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2023
   Article
3. Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis.Pharmaceutics · 2023
   Review
4. Current and Emerging Inhaled Antibiotics for Chronic PulmonaryAntibiotics (Basel, Switzerland) · 2023
   Review
5. Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis.Microbiology spectrum · 2023
   Article
6. Drug Repurposing Approaches towards Defeating Multidrug-Resistant Gram-Negative Pathogens: Novel Polymyxin/Non-Antibiotic Combinations.Pathogens (Basel, Switzerland) · 2022
   Review
7. Editorial: Women in pharmacology of infectious diseases: 2021.Frontiers in pharmacology · 2022
   Article
8. Enhanced Biosynthesis of Fatty Acids Contributes to Ciprofloxacin Resistance inFrontiers in microbiology · 2022
   Article
9. Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistantFrontiers in microbiology · 2022
   Article
10. Combined transcriptome and metabolome analyses reveal the potential mechanism for the inhibition of Penicillium digitatum by X33 antimicrobial oligopeptide.Bioresources and bioprocessing · 2021
    Article
11. Inactivation of Nitrite-Dependent Nitric Oxide Biosynthesis Is Responsible for Overlapped Antibiotic Resistance between Naturally and Artificially Evolved Pseudomonas aeruginosa.mSystems · 2021
    Article
12. Antibiotic Adjuvant Activity Revealed in a Photoaffinity Approach to Determine the Molecular Target of Antipyocyanin Compounds.ACS infectious diseases · 2021
    Article
13. Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis.Frontiers in pharmacology · 2021
    Article
14. Glucose-Potentiated Amikacin Killing of Cefoperazone/Sulbactam ResistantFrontiers in microbiology · 2021
    Article
15. The Balance between the Safety of Mother, Fetus, and Newborn Undergoing Cystic Fibrosis Transmembrane Conductance Regulator Treatments during Pregnancy.ACS pharmacology & translational science · 2020
    Review
16. Targeting Antibiotic Resistance: From Diagnostics to Novel Antibiotics.ACS pharmacology & translational science · 2020
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract